INT118369

From wiki-pain
Revision as of 02:37, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2004
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 12
Disease Relevance 3.51
Pain Relevance 0.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (E2F1) nucleoplasm (E2F1) mitochondrion (E2F1)
nucleus (E2F1) DNA binding (E2F1) transcription factor binding (E2F1)
Anatomy Link Frequency
hepatocytes 1
NG108-15 1
E2F1 (Homo sapiens)
Pain Link Frequency Relevance Heat
MU agonist 1 99.82 Very High Very High Very High
opioid receptor 1 97.80 Very High Very High Very High
Paracetamol 2 92.56 High High
Opioid 1 92.16 High High
agonist 15 87.00 High High
Delta opioid receptors 1 83.80 Quite High
Inflammation 9 5.00 Very Low Very Low Very Low
Central nervous system 8 5.00 Very Low Very Low Very Low
cytokine 8 5.00 Very Low Very Low Very Low
ischemia 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 287 99.80 Very High Very High Very High
Metastasis 28 98.34 Very High Very High Very High
Lung Cancer 15 97.76 Very High Very High Very High
Hyperplasia 3 84.88 Quite High
Death 5 82.56 Quite High
Apoptosis 45 81.36 Quite High
Diabetes Mellitus 2 63.44 Quite High
Breast Cancer 8 52.24 Quite High
Carcinoma 7 45.68 Quite Low
Reprotox - General 1 5 17.76 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Functional inactivation of pRB1 in various human cancers leads to deregulated E2F1 activity [46].
Regulation (deregulated) of E2F1 associated with cancer
1) Confidence 0.56 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.50 Pain Relevance 0
delta-Opioid agonist induced regulation of E2F1 DNA binding activity in NG108-15 cells.
Regulation (regulation) of E2F1 in NG108-15 associated with mu agonist
2) Confidence 0.52 Published 2005 Journal Brain Res. Mol. Brain Res. Section Title Doc Link 15893610 Disease Relevance 0 Pain Relevance 0.28
The transcription factors, E2F1 and ID1 mRNA were increased three-fold and six-fold (P < 0.05, P < 0.01), respectively, in AFB(1) treated primary human hepatocytes but were not altered in HepG2.
Neg (not) Regulation (altered) of E2F1 in hepatocytes
3) Confidence 0.45 Published 2004 Journal Mutat. Res. Section Abstract Doc Link 15120964 Disease Relevance 0 Pain Relevance 0.16
137 of TSP1 promoter is critical for E2F1 up-regulation.
Regulation (regulation) of E2F1
4) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
To elucidate E2F-1's function, searching for E2F-1's bona fide targets has been extensively conducted.
Regulation (searching) of E2F-1
5) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.20 Pain Relevance 0
Furthermore, we found that the knockdown of endogenous E2F-1 could inhibit TSP-1 promoter activity significantly, confirming the relevance of E2F-1 mediated regulation of TSP-1 in vivo.
Regulation (regulation) of E2F-1
6) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
In consistence with up-regulation of TSP-1 activity by over-expression of E2F-1, the knockdown of endogenous E2F-1 inhibited TSP-1 promoter activity significantly, implying that E2F-1 mediated regulation of TSP-1 is relevant in vivo.
Regulation (regulation) of E2F-1
7) Confidence 0.25 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2955548 Disease Relevance 0.15 Pain Relevance 0
TSP1 is the first identified naturally occurring angiogenic inhibitor, its role in inhibiting angiogenesis, resulting in inhibition of tumor growth and metastases has been well-defined [11], and therefore, the identification of TSP1 as a direct target of E2F-1 might open a new window for demonstrating the role of E2F-1 on anti-angiogenesis, relevant to its function in tumor suppression.
Regulation (target) of E2F-1 associated with cancer and metastasis
8) Confidence 0.25 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.69 Pain Relevance 0
Here, we presented data to show that pRB1 could also suppress E2F-1's transactivity on TSP1 promoter in a dose-dependent manner, which is consistent with the role of pRB1 in modulating expression of E2F-1 targets, further confirming that TSP1 serves as a bona fide target of E2F-1.
Regulation (target) of E2F-1
9) Confidence 0.25 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.63 Pain Relevance 0
Taken together, these results suggested that TSP1 is a direct target of E2F-1.
Regulation (target) of E2F-1
10) Confidence 0.25 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.05 Pain Relevance 0
It is also noted in Table 1 that the miR-17-92 cluster targets E2F1, a member of the E2F transcription factor family.
Regulation (targets) of E2F1
11) Confidence 0.19 Published 2008 Journal Current Genomics Section Body Doc Link PMC2674802 Disease Relevance 0.35 Pain Relevance 0
was accompanied by synergistic modulation of E2F-1, p27?
Regulation (modulation) of E2F-1
12) Confidence 0.04 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528242 Disease Relevance 0.94 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox